ISOSABUTATE



NAME OF DRUG : ISOSABUTATE

ALSO KNOWN AS : ISOSABUTATE

LABORATORY : NORTHSEA_THERAPEUTICS

STATUS AND ADVANCEMENT

Type of drug : SEFA Structurally Engineered Fatty Acid

Clinical trials advancement : Initiating Phase 2b

Estimated time to market : 112 months.

LABORATORY ABSTRACT ON THE DRUG

After extensive in vivo/in vitro profiling the company’s lead compound, icosabutate, was selected based on its ability to modulate pivotal pathways associated with inflammatory liver disease, including non-alcoholic steatohepatitis (NASH).  Icosabutate is a potent structurally engineered fatty acid, specifically designed to maximise substrate availability for key pathways involved in the pathogenesis of NASH.

RECENT NEWS ON ISOSABUTATE

SOME PUBLICATIONS RELATED WITH ISOSABUTATE

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH ISOSABUTATE


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE